Anti-PGAP6/ ™EM8A/ GPI-PLA2 monoclonal antibody

Anti-PGAP6/ ™EM8A/ GPI-PLA2 antibody for FACS & in-vivo assay

Target products collectionGo to ™EM8A/™EM8A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1843-Ab-1/ GM-Tg-hg-MP1843-Ab-2Anti-Human ™EM8A monoclonal antibodyHuman
GM-Tg-rg-MP1843-Ab-1/ GM-Tg-rg-MP1843-Ab-2Anti-Rat ™EM8A monoclonal antibodyRat
GM-Tg-mg-MP1843-Ab-1/ GM-Tg-mg-MP1843-Ab-2Anti-Mouse ™EM8A monoclonal antibodyMouse
GM-Tg-cynog-MP1843-Ab-1/ GM-Tg-cynog-MP1843-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM8A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1843-Ab-1/ GM-Tg-felg-MP1843-Ab-2Anti-Feline ™EM8A monoclonal antibodyFeline
GM-Tg-cang-MP1843-Ab-1/ GM-Tg-cang-MP1843-Ab-2Anti-Canine ™EM8A monoclonal antibodyCanine
GM-Tg-bovg-MP1843-Ab-1/ GM-Tg-bovg-MP1843-Ab-2Anti-Bovine ™EM8A monoclonal antibodyBovine
GM-Tg-equg-MP1843-Ab-1/ GM-Tg-equg-MP1843-Ab-2Anti-Equine ™EM8A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1843-Ab-1/ GM-Tg-hg-MP1843-Ab-2; GM-Tg-rg-MP1843-Ab-1/ GM-Tg-rg-MP1843-Ab-2;
GM-Tg-mg-MP1843-Ab-1/ GM-Tg-mg-MP1843-Ab-2; GM-Tg-cynog-MP1843-Ab-1/ GM-Tg-cynog-MP1843-Ab-2;
GM-Tg-felg-MP1843-Ab-1/ GM-Tg-felg-MP1843-Ab-2; GM-Tg-cang-MP1843-Ab-1/ GM-Tg-cang-MP1843-Ab-2;
GM-Tg-bovg-MP1843-Ab-1/ GM-Tg-bovg-MP1843-Ab-2; GM-Tg-equg-MP1843-Ab-1/ GM-Tg-equg-MP1843-Ab-2
Products NameAnti-™EM8A monoclonal antibody
Formatmab
Target Name™EM8A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-™EM8A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PGAP6/ ™EM8A/ GPI-PLA2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1843
    Target Name™EM8A
    Gene ID58986,60455,303004,722297,479896,101095788,508215,100066625
    Gene Symbol and SynonymsGPI-PLA2,M83,PGAP6,Rxylt1,™EM6,™EM8,™EM8A
    Uniprot AccessionQ9HCN3
    Uniprot Entry NamePGAP6_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000129925
    Target ClassificationN/A

    The target: ™EM8A, gene name: ™EM8A, also named as GPI-PLA2, M83, PGAP6, ™EM6, ™EM8. Predicted to enable phospholipase A2 activity. Located in extracellular exosome and lysosomal membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.